152 related articles for article (PubMed ID: 3926311)
1. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
Haas CD; Baker L; Thigpen T
Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
[TBL] [Abstract][Full Text] [Related]
3. Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
Slavik M; Arsenau JC; Blessing J; Lewis GC
Am J Clin Oncol; 1982 Oct; 5(5):483-6. PubMed ID: 6897490
[No Abstract] [Full Text] [Related]
4. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
[No Abstract] [Full Text] [Related]
5. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G
Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study.
Gagliano RG; Panettiere FJ; Haas CD; Baker L; Hewlett J; Stuckey WJ; O'Bryan RM; Bottomley R; Heilburn LK
Cancer Clin Trials; 1981; 4(4):401-5. PubMed ID: 7318121
[TBL] [Abstract][Full Text] [Related]
7. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.
Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G
Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198
[No Abstract] [Full Text] [Related]
9. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.
Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B
Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224
[No Abstract] [Full Text] [Related]
11. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study.
Stehman FB; Blessing JA; Delgado G; Louka M
Cancer Treat Rep; 1983; 67(7-8):737-8. PubMed ID: 6871892
[No Abstract] [Full Text] [Related]
12. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
[TBL] [Abstract][Full Text] [Related]
13. Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
Bruckner HW; Lokich JJ; Stablein DM
Cancer Treat Rep; 1982 Sep; 66(9):1713-7. PubMed ID: 7116348
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: a Gynecologic Oncology Group study.
Conroy JF; Blessing JA; Kessinger A; Homesley HD
Cancer Treat Rep; 1984 Feb; 68(2):439-40. PubMed ID: 6697335
[No Abstract] [Full Text] [Related]
16. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
Thigpen JT; Al-Sarraf M; Hewlett JS
Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of dianhydrogalactitol in malignant glioma.
Espana P; Wiernik PH; Walker MD
Cancer Treat Rep; 1978 Aug; 62(8):1199-200. PubMed ID: 210944
[No Abstract] [Full Text] [Related]
18. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
Oldham DS; Wampler GL
Med Pediatr Oncol; 1983; 11(4):297-8. PubMed ID: 6310359
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of dianhydrogalactitol (NSC-132313).
Haas CD; Stephens RL; Hollister M; Hoogstraten B
Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
